Eftilagimod alpha (soluble LAG-3) and pembrolizumab in first-line recurrent or metastatic head and neck squamous cell carcinoma: primary results from cohort B (CPS less-than 1) of the TACTI-003 study
Metcalf, Robert Laban, S. Kristensen, C. A. Ciuleanu, T. E. BraƱa, I. Rivas, A. S. Dieter, S. M. Bols, A. Forster, M. D. Covela, M. R.
Metcalf, Robert
Laban, S.
Kristensen, C. A.
Ciuleanu, T. E.
BraƱa, I.
Rivas, A. S.
Dieter, S. M.
Bols, A.
Forster, M. D.
Covela, M. R.
Citations
Altmetric:
Abstract
Description
Date
2024
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Metcalf R, Laban S, Kristensen CA, Ciuleanu TE, BraƱa I, Rivas AS, et al. Eftilagimod alpha (soluble LAG-3) and pembrolizumab in first-line recurrent or metastatic head and neck squamous cell carcinoma: Primary results from Cohort B (CPS less-than 1) of the TACTI-003 study. ANNALS OF ONCOLOGY. 2024 AUG;35(8):754-5. PubMed PMID: WOS:001343513200002. English.